Judge Bars Mylan's Oracea Generic In Galderma IP Case
Judge Leonard P. Stark, who found Mylan liable for infringement in August, ordered the U.S. Food and Drug Administration to withdraw its approval for Mylan's abbreviated new drug application and permanently enjoined the generic version until Galderma's patent expires in 2027.
Mylan argued that it was...
Already a subscriber? Click here to login